NAD+ Dosing & Protocols — Research Reference

Nicotinamide adenine dinucleotide (NAD+) is a redox cofactor and substrate for sirtuins, PARPs, and CD38. Research dosing differs sharply by route because oral and parenteral NAD+ have very different pharmacokinetic profiles.

Reconstitution for Research

NAD+ is typically supplied as a hygroscopic lyophilized powder in 100 mg, 500 mg, or 1000 mg vials. A 500 mg vial reconstituted with 10 mL bacteriostatic water (or sterile saline for IV infusion research) yields 50 mg/mL. NAD+ is light- and pH-sensitive; reconstituted solution should be used promptly and protected from light. Sodium-buffered preparations are more stable than acidic reconstitutions.

Reference Dose Ranges in Published Research

| Route | Typical range | Notes | |---|---|---| | Subcutaneous | 50–100 mg per dose, daily | Most-cited research tier; lower bioavailability than IV | | Intramuscular | 50–100 mg per dose, daily | Comparable bioavailability to SC | | Intravenous infusion | 250–1000 mg over 2–8 hours | Slow infusion required — bolus produces significant adverse-event burden | | Intranasal | 100–400 mg per day, divided | Higher local CNS exposure in some models |

Scheduling

IV infusion protocols universally use slow administration (2–8 hours per dose) because rapid infusion produces chest pressure, muscle cramping, and nausea in nearly all subjects. Published loading-phase IV research often runs 5–10 consecutive daily infusions followed by weekly or monthly maintenance. SC and IM protocols use daily dosing for 4–12 weeks with periodic NAD+ or NAD+/NADH ratio measurement.

Precursor Alternatives

The published research record also covers NAD+ precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — at oral doses of 250–1000 mg/day. These bypass NAD+'s poor oral bioavailability by entering the salvage pathway upstream of NAD+ synthesis.

Quality and Identity Verification

UV absorbance (260 nm peak, A260/A340 ratio) and HPLC purity ≥98% are the standard acceptance criteria. NAD+ readily oxidizes; the oxidized form (NAD+) and reduced form (NADH) differ in UV spectrum and must be distinguished. Endotoxin testing is mandatory for any parenteral preparation.

Research Use Only. All content is for laboratory research and educational reference. Compounds discussed are not intended for human or veterinary consumption, prophylactic, or therapeutic use.

References

1. Rajman L, Chwalek K, Sinclair DA. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metab. 2018;27(3):529–547.
2. Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018;27(3):513–528.
3. Grant R, Berg J, Mestayer R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Front Aging Neurosci. 2019;11:257.